Sentinel lymph node dissection non-inferior to axillary node

September 13, 2017

(HealthDay)—Ten-year overall survival for primary breast cancer patients treated with sentinel lymph node dissection (SLND) alone is similar to that seen in those treated with axillary lymph node dissection (ALND), according to a study published in the Sept. 12 issue of the Journal of the American Medical Association.

Armando E. Giuliano, M.D., from the Cedars-Sinai Medical Center in Los Angeles, and colleagues compared the 10-year overall survival of patients with metastases treated with breast-conserving therapy and SLND alone without ALND (446 patients) versus women treated with ALND (445 patients). The women, with clinical T1 or T2 invasive , all had planned lumpectomy, tangential whole-breast irradiation, and adjuvant systemic therapy.

The researchers found that at a median of 9.3 years of follow-up, the 10-year overall survival was 86.3 percent in the SLND-alone group and 83.6 percent in the ALND group (hazard ratio, 0.85; one-sided 95 percent confidence interval, 0 to 1.16; noninferiority P = 0.02). In the SLND-alone group, 10-year disease-free survival was 80.2 percent, compared to 78.2 percent in the ALND group (hazard ratio, 0.85; 95 percent confidence interval, 0.62 to 1.17; P = 0.32). The two groups had similar 10-year regional recurrence.

"These findings do not support routine use of axillary in this patient population based on 10-year outcomes," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection

December 7, 2016
A sentinel lymph node biopsy (SLNB) during surgery that showed no signs of cancer was associated with a low risk for breast cancer recurrence in the axillary (armpit) lymph nodes for patients with large, operable breast tumors ...

Targeted axillary dissection of lymph nodes after chemotherapy improves staging accuracy of node-positive breast cancer

January 26, 2016
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic evaluation in clinically node-positive breast cancer, and reduces the need ...

Study shows radiotherapy and surgery provide regional control for breast cancer patients

June 3, 2013
Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control ...

Breast cancer patients with positive ultrasound guided axillary node biopsy need dissection

May 3, 2012
Contrary to a trend in treatment, breast cancer patients with suspicious lymph nodes should have an ultrasound-guided axillary node biopsy, and if that biopsy is positive these patients should undergo an axillary dissection, ...

Breast cancer update: Sentinel node biopsy guidelines encourage 'less is more' approach

December 12, 2016
New recommendations from breast cancer experts on sentinel lymph node biopsy reinforce the most recent "less-is-more" guidelines for early-stage disease. But a Fred Hutch researcher who helped create the guidelines said many ...

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.